Efectos de ivermectina como tratamiento coadyuvante en epilepsia refractaria basada en datos del Hospital de Infectología José Daniel Rodríguez Maridueña del año 2017 - 2018
No hay miniatura disponible
Fecha
2019
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Carrera de Medicina
Resumen
Introducción. La terapéutica con la ivermectina como coadyuvante se considera una opción del tratamiento valido para los pacientes con epilepsia intratable cuyas convulsiones no responden con éxito a la terapia con fármacos anticonvulsivantes, esta condición se conoce como epilepsia intratable o refractaria. El objetivo se determinó la eficacia y seguridad de ivermectina como facilitador de los antiepiléptico en el manejo de la epilepsia refractaria en el servicio de neurología del hospital de infectología´´ Dr. José Daniel Rodríguez Maridueña ´´ desde enero 2018 a diciembre 2018. Materiales y métodos, se desarrolló una investigación descriptiva y analítica, no experimental de corte transversal, en pacientes con epilepsia fármaco resistente. Resultados se seleccionaron 21 pacientes con epilepsia refractaria para trata con ivermectina más los antiepiléptico previamente empleado sin aparente mejoría, correspondiendo a 14 masculino (66,7%) y 7 femenino (33,3%), con una reducción de frecuencia e intensidad de crisis del 61,90% mejorando a una buena calidad de vida. Conclusiones. Ivermectina es una fármaco ¿segura, con efectos adversos transitorios, Muchos factores necesitan ser evaluados en los pacientes epilépticos, número e intensidad y repetición de las crisis, con calidad de vida para indicar el tratamiento, se debe continuar realizando estudios.
Introduction. Therapy with ivermectin as adjuvant is considered an option of valid treatment for patients with intractable epilepsy whose seizures do not respond successfully to therapy with anticonvulsant drugs, this condition is known as epilepsy intractable or refractory. The objective was to determine the efficacy and safety of ivermectin as a facilitator of antiepileptic drugs in the management of refractory epilepsy in the neurology department of the hospital of infectology "Dr. José Daniel Rodriguéz Maridueña" from January 2018 to December 2018. Materials and methods, a descriptive and analytical, non-experimental cross-sectional investigation was developed in patients with resistant drug epilepsy. RESULTS: Twenty-one patients with refractory epilepsy were selected for ivermectin plus antiepileptic drugs previously used without apparent improvement, corresponding to 14 male (66.7%) and 7 female (33.3%), with a reduction in frequency and intensity of crisis 61.90% improving to a good quality of life. Conclusions Ivermectin is a safe drug, with transient adverse effects. Many factors need to be evaluated in epileptic patients, number and intensity and repetition of seizures, with quality of life to indicate treatment, studies should continue to be carried out. Key words: Refractory epilepsy, vagus nerve, electrical stimulation.
Introduction. Therapy with ivermectin as adjuvant is considered an option of valid treatment for patients with intractable epilepsy whose seizures do not respond successfully to therapy with anticonvulsant drugs, this condition is known as epilepsy intractable or refractory. The objective was to determine the efficacy and safety of ivermectin as a facilitator of antiepileptic drugs in the management of refractory epilepsy in the neurology department of the hospital of infectology "Dr. José Daniel Rodriguéz Maridueña" from January 2018 to December 2018. Materials and methods, a descriptive and analytical, non-experimental cross-sectional investigation was developed in patients with resistant drug epilepsy. RESULTS: Twenty-one patients with refractory epilepsy were selected for ivermectin plus antiepileptic drugs previously used without apparent improvement, corresponding to 14 male (66.7%) and 7 female (33.3%), with a reduction in frequency and intensity of crisis 61.90% improving to a good quality of life. Conclusions Ivermectin is a safe drug, with transient adverse effects. Many factors need to be evaluated in epileptic patients, number and intensity and repetition of seizures, with quality of life to indicate treatment, studies should continue to be carried out. Key words: Refractory epilepsy, vagus nerve, electrical stimulation.
Descripción
PDF
Palabras clave
Epilepsia refractaria, Ivermectina, Tratamiento coadyuvante, Hospital de Infectología Dr. José Daniel Rodríguez Maridueña, Cantón Guayaquil, Ecuador, Epidemiología descriptiva, Epidemiología analítica